Table 2.

Univariate and multivariate analyses of baseline factors associated with overall intracranial response rate

				Univariate		Multivariate
Category		Patients (N)	N responding (%)	OR (95% CI)	p value	OR (95% CI)	p value
Age	<54	59	34 (58)	1.066 (0.524–2.166)	0.8599	1.143 (0.512–2.554)	0.7443
	>=54	66	37 (56)
Gender	Female	53	28 (53)	0.755 (0.369–1.546)	0.4425	0.735 (0.334–1.618)	0.4447
	Male	72	43 (60)
ECOG	0	82	50 (61)	1.637 (0.777–3.447)	0.1946	1.034 (0.399–2.681)	0.9456
	>=1	43	21 (49)
BRAF mutation status	V600E	104	61 (59)	1.56 (0.609–3.999)	0.3541	1.686 (0.574–4.957)	0.3421
	Other	21	10 (48)
Brain metastases	1	62	37 (60)	1.138 (0.432–2.997)	0.568	1.287 (0.355–4.668)	0.5891
	2	40	21 (53)	0.85 (0.303–2.386)	0.5717	0.988 (0.286–3.410)	0.7598
	>=3	23	13 (57)
SLD of target intracranial lesion	<median	62	35 (56)	0.972 (0.479–1.973)	0.9378	0.632 (0.184–2.167)	0.4655
	>=median	63	36 (57)
Largest intracranial lesion	<median	60	35 (58)	1.128 (0.555–2.291)	0.7396	1.177 (0.392–3.530)	0.7717
	>=median	65	36 (55)
Extracranial metastases	Yes	97	55 (57)	0.982 (0.420–2.297)	0.9669	1.212 (0.435–3.379)	0.7135
	No	28	16 (57)
Elevated serum LDH	Yes	42	21 (50)	0.660 (0.312–1.394)	0.2761	0.71 (0.302–1.676)	0.436
	No	83	50 (60)
Steroid use at baseline	Yes	33	13 (39)	0.381 (0.168–0.862)	0.0206	0.323 (0.105–0.996)	0.0491
	No	92	58 (63)
Previously treatment anti-cancer	Yes	32	21 (66)	1.642 (0.712–3.786)	0.2449	1.831 (0.710–4.719)	0.2105
	No	93	50 (54)
	Yes	28	14 (50)	0.702 (0.302–1.632)	0.4108	1.186 (0.385–3.654)	0.7669
Previous treatment to brain	No	97	57 (59)
XRT to brain	Yes	34	15 (44)	0.493 (0.222–1.096)	0.0827	0.477 (0.156–1.464)	0.196
	No	91	56 (62)
Previous Surgery to brain	Yes	121	69 (57)	1.327 (0.181–9.734)	0.7809	1.487 (0.172–12.850)	0.7182
	No	4	2 (50)
Presence of uncontrolled symptoms from brain	Yes	24	13 (54)	0.876 (0.358–2.143)	0.7721	1.603 (0.479–5.367)	0.4438
	No	101	58 (57)